Login to Your Account



Novabay Shares Tank on Impetigo Phase IIb Miss

By Catherine Shaffer
Staff Writer

Friday, November 8, 2013
Novabay Pharmaceuticals Inc. took a pounding in the stock market Thursday after it reported the failure of a Phase IIb study of its impetigo candidate, auriclosene. The study showed that the drug was safe and well tolerated but did not meet the primary clinical endpoint of the trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription